| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 14,320 | 13,940 | 14,160 | 16,730 | 13,540 |
| Sales Growth | +2.73% | -1.55% | -15.36% | +23.56% | +7.12% |
| Net Income | -3,710 | -1,760 | -27,350 | -18,700 | -1,500 |
| Net Income Growth | -110.80% | +93.56% | -46.26% | -1,146.67% | +83.41% |
Lensar Inc (LNSR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
LENSAR Inc. is a commercial-stage medical device company. It focuses on designing, developing and marketing an advanced femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. LENSAR Inc. is based in Orlando, Florida.
Fiscal Year End Date: 12/31